Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zafirlukast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 known ✓ | Q9Y271 | 5/20 | 1.00 |
| ▸ | PLA2G4A | P47712 | 5/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 4/20 | 1.00 |
| ▸ | PPARG | P37231 | 4/20 | 1.00 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | PTGES | O14684 | 1/20 | 1.00 |
| ▸ | XPO1 | O14980 | 1/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | RARB | P10826 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zafirlukast SCHEMBL4175 | 1.00 | PLA2G4A (1.00) | PLA2G4ACYSLTR1EPHX2PPARGCYSLTR2 | |
| Zafirlukast SCHEMBL6600322 | 1.00 | PLA2G4A (1.00) | PLA2G4ACYSLTR1EPHX2PPARGCYSLTR2 | |
| Zafirlukast SCHEMBL29372773 | 1.00 | PLA2G4A (1.00) | PLA2G4ACYSLTR1EPHX2PPARGCYSLTR2 | |
| Zafirlukast SCHEMBL30885065 | 1.00 | PLA2G4A (1.00) | PLA2G4ACYSLTR1EPHX2PPARGCYSLTR2 | |
| Zafirlukast SCHEMBL6765680 | 0.99 | PLA2G4A (0.99) | PLA2G4ACYSLTR1EPHX2PPARGCYSLTR2 | |
| Zafirlukast SCHEMBL4586973 | 0.99 | PLA2G4A (0.99) | PLA2G4ACYSLTR1EPHX2PPARGCYSLTR2 | |
| Zafirlukast SCHEMBL8951202 | 0.99 | PLA2G4A (0.99) | PLA2G4ACYSLTR1EPHX2PPARGCYSLTR2 | |
| Zafirlukast SCHEMBL6381072 | 0.99 | PLA2G4A (0.99) | PLA2G4ACYSLTR1EPHX2PPARGCYSLTR2 | |
| Zafirlukast SCHEMBL6378803 | 0.99 | PLA2G4A (0.99) | PLA2G4ACYSLTR1EPHX2PPARGCYSLTR2 | |
| Zafirlukast SCHEMBL6715413 | 0.99 | PLA2G4A (0.97) | PLA2G4ACYSLTR1EPHX2PPARGCYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | MODEL MEDICINES, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | RECEPTIVE BIO INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4667008-A2 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025122600-A1 | COMPOSITIONS AND METHODS FOR TREATING ABERRANT NITROSYLATION | CASE WESTERN RESERVE UNIVERSITY (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20230248712-A1 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES, INC. | 2023-08-10 | — | — | US | disclosed |
| EP-4157448-A1 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| WO-2022173818-A1 | USE OF BILIVERDIN REDUCTASE B INHIBITORS TO ALLOW MALARIA ERADICATION IN PATIENTS WITH G6PD DEFICIENCY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | SARS1, EIF2AK2, SNRPE | CYSLTR1 1868/4885PLA2G4A 1046/4885EPHX2 3715/4885 |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | CA4, FLT4, CAMK4 | CYSLTR1 92/4885PLA2G4A 3934/4885EPHX2 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.